JP2020524132A - アルツハイマー病を治療するための組成物および方法 - Google Patents

アルツハイマー病を治療するための組成物および方法 Download PDF

Info

Publication number
JP2020524132A
JP2020524132A JP2019565526A JP2019565526A JP2020524132A JP 2020524132 A JP2020524132 A JP 2020524132A JP 2019565526 A JP2019565526 A JP 2019565526A JP 2019565526 A JP2019565526 A JP 2019565526A JP 2020524132 A JP2020524132 A JP 2020524132A
Authority
JP
Japan
Prior art keywords
ptpσ
therapeutic
app
therapeutic agent
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019565526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524132A5 (enExample
Inventor
シェン，インジー
グ，ヤンチェン
シルバー，ジェリー
ティー． ラン，ブラッドリー
ティー． ラン，ブラッドリー
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
ケース ウエスタン リザーブ ユニバーシティ
オハイオ ステート ユニバーシティ
オハイオ ステート ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, ケース ウエスタン リザーブ ユニバーシティ, オハイオ ステート ユニバーシティ, オハイオ ステート ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2020524132A publication Critical patent/JP2020524132A/ja
Publication of JP2020524132A5 publication Critical patent/JP2020524132A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019565526A 2017-06-05 2018-06-05 アルツハイマー病を治療するための組成物および方法 Pending JP2020524132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515272P 2017-06-05 2017-06-05
US62/515,272 2017-06-05
PCT/US2018/036116 WO2018226735A1 (en) 2017-06-05 2018-06-05 Compositions and methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2020524132A true JP2020524132A (ja) 2020-08-13
JP2020524132A5 JP2020524132A5 (enExample) 2020-09-24

Family

ID=64567326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565526A Pending JP2020524132A (ja) 2017-06-05 2018-06-05 アルツハイマー病を治療するための組成物および方法

Country Status (8)

Country Link
US (1) US20200093890A1 (enExample)
EP (1) EP3634979A4 (enExample)
JP (1) JP2020524132A (enExample)
KR (1) KR20200045446A (enExample)
CN (1) CN110945011A (enExample)
AU (1) AU2018281330A1 (enExample)
CA (1) CA3064479A1 (enExample)
WO (1) WO2018226735A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120957751A (zh) * 2023-04-03 2025-11-14 神经再生制药公司 用于神经系统修复的蛋白酪氨酸磷酸酶楔形结构域肽二聚体
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524847A (ja) * 2007-03-21 2010-07-22 エラン・フアーマシユーチカルズ・インコーポレーテツド Ｌｔｐ阻害の抑制方法
JP2012530105A (ja) * 2009-06-15 2012-11-29 フエー・イー・ベー・フエー・ゼツト・ウエー Ｂａｃｅ１抑制性抗体
JP2015510941A (ja) * 2012-03-19 2015-04-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
JP2015516391A (ja) * 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002308460A1 (en) * 2001-04-12 2002-10-28 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20130171163A1 (en) * 2010-08-06 2013-07-04 Marschall Runge Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis
EP3454885A4 (en) * 2016-05-12 2019-12-25 Ohio State Innovation Foundation PEPTIDES AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524847A (ja) * 2007-03-21 2010-07-22 エラン・フアーマシユーチカルズ・インコーポレーテツド Ｌｔｐ阻害の抑制方法
JP2012530105A (ja) * 2009-06-15 2012-11-29 フエー・イー・ベー・フエー・ゼツト・ウエー Ｂａｃｅ１抑制性抗体
JP2015510941A (ja) * 2012-03-19 2015-04-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
JP2015516391A (ja) * 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GU ET AL: "Alzheimer’s disease pathogenesis is dependent on neuronal receptor PTPσ", BIORXIV [ONLINE]［RETRIEVED ON 22 APRIL 2021］, JPN6021016106, 2016, ISSN: 0004689784 *

Also Published As

Publication number Publication date
EP3634979A1 (en) 2020-04-15
CA3064479A1 (en) 2018-12-13
EP3634979A4 (en) 2021-04-14
US20200093890A1 (en) 2020-03-26
AU2018281330A1 (en) 2019-12-19
KR20200045446A (ko) 2020-05-04
CN110945011A (zh) 2020-03-31
WO2018226735A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
Chen et al. Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Fol et al. Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
US7276643B2 (en) Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
US20220104468A1 (en) Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
KR20140051840A (ko) 신경변성 타우오패씨를 치료하는 방법
JP2022518729A (ja) 中枢神経系疾患の治療法
US20180170983A1 (en) New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
US20130195866A1 (en) Methods to inhibit neurodegeneration
JP2020524132A (ja) アルツハイマー病を治療するための組成物および方法
US20240050524A1 (en) Delivery of abeta variants for aggregation inhibition
CN112153897B (zh) 用于治疗神经病学和其他病症的组合物和方法
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
US20140314790A1 (en) Caspase 9 inhibition and bri2 peptides for treating dementia
WO2016014908A1 (en) Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
JP2020524667A (ja) アルファ−シヌクレインの調節因子
US20250241968A1 (en) Compositions and methods for treating neurodegeneration
He Peripheral gene therapy for the treatment of Alzheimer’s disease
KR20250040552A (ko) 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술
WO2024243435A2 (en) Compositions and methods for treatment and prevention of neurodegenerative diseases and disorders
WO2025178998A1 (en) Compositions and methods for treating cogntive decline and/or memory deficits
Fang SSH1 Impedes p62/SQSTM1 Flux and Tau Clearance Independent of Cofilin Activation
Yiu Mechanisms of Memory Deficits in Mouse Models of Alzheimer's Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125